MDASI Chimeric Antigen Receptor T-cell Module
The MD Anderson Symptom Inventory for chimeric antigen receptor T-cell therapy (MDASI-CAR) is a treatment-specific MDASI module. Use the MDASI-CAR to assess the severity of symptoms experienced by patients undergoing chimeric antigen receptor T-cell therapy and the interference with daily living caused by these symptoms.
Along with the core MDASI’s 13 symptom items and 6 interference items, the MDASI-CAR also assesses 10 symptoms relevant to chimeric antigen receptor T-cell therapy.
| Core MDASI Symptoms | CAR T-Cell Symptoms | MDASI Interference |
|---|---|---|
| Pain | Diarrhea | Relations with other people |
| Fatigue | Tremors | Enjoyment of life |
| Nausea | Fevers or chills | Mood |
| Disturbed sleep | Headache | Walking |
| Distress (feeling upset) | Balance problems or falling | Activity |
| Shortness of breath | Difficulty paying attention (concentrating) | Work (including housework) |
| Difficulty remembering | Dizziness | |
| Lack of appetite | Coughing | |
| Drowsiness | Change in sexual function | |
| Dry mouth | Difficulty speaking (finding the words) | |
| Sadness | ||
| Vomiting | ||
| Numbness/tingling |
Order the MDASI-CAR
Use our convenient online form to order the MDASI-CAR for use in your clinical research, clinical practice, funded and non-funded academic research, commercial research, or reproduction in educational materials or other publications.
MDASI-CAR Features
- Purpose: To assess the severity of multiple symptoms related to chimeric antigen receptor T-cell therapy and the impact of these symptoms on daily functioning
- Population: Patients with symptoms caused by chimeric antigen receptor T-cell therapy
- Assessment areas: Severity of multiple symptoms and the impact of symptoms on daily functioning during the last 24 hours
- Method: Self-report or interview with research staff; paper-and-pencil form or electronic data entry*
- Time required: Five minutes or less
- Scoring: Please see the MDASI User's Guide
- Reliability: Cronbach alpha reliability ranges from 0.89 to 0.93
*Electronic data capture offers several benefits:
- Allows symptom monitoring when the patient is away from the hospital
- Is convenient for patients, who can choose web access, personalized patient portals, or smartphones to access questionnaires
- Minimizes missing data, especially in longitudinal studies
- Provides accurate, real-time symptom data at expected time points
- Generates immediate feedback, potentially allowing caregivers to address severe symptoms more effectively
MDASI-CAR Language Versions
Click on a linked language to view a sample in PDF format.
Don't see a language you need? Contact us at symptomresearch@mdanderson.org.
| Psychometrically and Linguistically Validated | Linguistically Validated |
|---|---|
| English | Chinese (in process) |
MDASI User Guide
In response to the US Food and Drug Administration's 2009 guidance for the pharmaceutical industry on the use of patient-reported outcomes measures in medical product development to support labeling claims, we have prepared a MDASI User Guide to document the development and psychometric properties of the MDASI and its modules. The User Guide addresses the recommendations in the FDA guidance and establishes the MDASI's adequacy as a measure to support medical product claims.
Selected MDASI-CAR References
Validation
Wang XS, Srour SA, Mendoza T, et al. Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy. Br J Haematol 201(4):738-746, 2023.
Whisenant MS, Srour SA, Williams LA, et al. The unique symptom burden of patients receiving CAR T-cell therapy. Semin Oncol Nurs 37(6):151216, 2021.
Wang XS, Srour SA, Whisenant M, et al. Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies. Transplant Cell Ther 27(11):930.e1-930.e10, 2021.
Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer: the M. D. Anderson Symptom Inventory. Cancer 89:1634-1646, 2000.
Every MDASI module contains:
all 13 core MDASI symptoms...
pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, difficulty remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness/tingling
...and all 6 MDASI interference items
general activity, mood, work, relations with others, walking, enjoyment of life
Recent success with chimeric antigen receptor (CAR) T-cell therapy has brought about a paradigm shift for patients with relapsed or refractory B-cell lymphoma or multiple myeloma — along with unique toxicities and symptom burden.
Samer A. Srour, M.B. Ch.B.
Assistant Professor, Stem Cell Transplantation and Cellular Therapy